Chapter 2 From Microbial Products to Novel Drugs that Target a Multitude of Disease Indications
- 1 January 2009
- book chapter
- Published by Elsevier BV in Methods in Enzymology
- Vol. 458, 29-58
- https://doi.org/10.1016/s0076-6879(09)04802-2
Abstract
No abstract availableThis publication has 59 references indexed in Scilit:
- In Vivo Manipulation of the Bleomycin Biosynthetic Gene Cluster in Streptomyces verticillus ATCC15003 Revealing New Insights into Its Biosynthetic PathwayOnline Journal of Public Health Informatics, 2008
- Analysis of the Cryptophycin P450 Epoxidase Reveals Substrate Tolerance and CooperativityJournal of the American Chemical Society, 2008
- Mutation and a high-throughput screening method for improving the production of Epothilones of SorangiumJournal of Industrial Microbiology & Biotechnology, 2007
- Natural Products as Sources of New Drugs over the Last 25 YearsJournal of Natural Products, 2007
- Antibiotic production improvement in the rare actinomycete Planobispora rosea by selection of mutants resistant to the Aminoglycosides Streptomycin and Gentamycin and to RifamycinJournal of Industrial Microbiology & Biotechnology, 2005
- Bioactive Microbial MetabolitesThe Journal of Antibiotics, 2005
- Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolitesJournal of Industrial Microbiology & Biotechnology, 2003
- Molecular and structural biology of bleomycin and its resistance determinantsJournal of Bioscience and Bioengineering, 2002
- Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activityFEBS Letters, 1976
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975